Meeting
2018 ASCO Annual Meeting
A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.
Authors
John Frederick De Groot
The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX
John Frederick De Groot , Timothy Francis Cloughesy , Marshall W. Pitz , Yoshitaka Narita , Takeshi Nonomura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03149003
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS2071)
DOI
10.1200/JCO.2018.36.15_suppl.TPS2071
Abstract #
TPS2071
Poster Bd #
229a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
First Author: Wolfgang Wick
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
First Author: Wolfgang Wick
Poster
2016 ASCO Annual Meeting
Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma.
First Author: Khe Hoang-Xuan
Poster
2013 ASCO Annual Meeting
A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET).
First Author: Kathryn Maree Field